Compare MARPS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | OGEN |
|---|---|---|
| Founded | 1956 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 2.7M |
| IPO Year | N/A | 2010 |
| Metric | MARPS | OGEN |
|---|---|---|
| Price | $4.99 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.2K | ★ 47.5K |
| Earning Date | 02-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $0.11 |
| 52 Week High | $6.49 | $9.16 |
| Indicator | MARPS | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 43.53 |
| Support Level | $4.17 | N/A |
| Resistance Level | $5.20 | $0.66 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 48.01 | 32.34 |
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.